Conference Day Two - Thursday, December 5
8.00 Check-In & Coffee
8.55 Chair’s Opening Remarks
Plenary Session: Academic Pioneers
9.05 Therapeutic Gene Editing for Cardiovascular and Metabolic Diseases: From the Leading Cause of Death to N-Of-1 Disorders
10.05 Advancing the Development of Safe and Effective Cell & Gene Therapies Using INDUCE-seqTM
10.05 Engineering and Evolution of Hyperactive, CRISPR-Associated Transposases (VIRTUAL)
10.35 Morning Refreshments
Innovation & Early Development Track
Translating to the Clinic Track
Progressing Epigenome Editors into the Clinic
Moderator: Luca Biasco, Nvelop Therapeutics
Outlining a Path to the Clinic
Moderator: Narin Ahmed, Tessera Therapeutics
11.20 Programmable Gene Activation, Silencing &
Multiplexing for Precise Gene Regulation
Shane Wright, Associate Scientist II, Chroma Medicine
11.20 AFNT-212: A Non-Viral Gene-Edited TCR-T Cell
Therapy
Ankit Gupta, Senior Director, Head of Gene Editing,
Affini-T Therapeutics
11.50 Epigenome editing with CRIPSR-GNDM® as a treatment platform for unmet medical conditions
Tetsuya Yamagata, Chief Scientific Officer, Modalis Therapeutics
11.50 Editing HBG1/2 and BCL11A for Beta
Hemoglobinopathies
Sheryl Bowley, Director, HSC Therapies, Editas Medicinee
12.20 CRISPR Epigenetic Modification to Treat Hepatitis B
Britta Jones, Senior Scientist, Tune Therapeutics
12.20 Compact Nucleases: Outlining a Roadmap Towards
Clinical Evaluation
Mark DeWitt, Associate Director, Mammoth Biosciences
12.50 Lunch
Innovation & Early Development Track
Translating to the Clinic Track
Validating the Next Generation of Delivery Vehicles
Moderator: Luca Biasco, Nvelop Therapeutics
Driving Novel Nucleases Towards the Clinic
Moderator: Narin Ahmed, Tessera Therapeutics
1.50 In Vivo RNA Delivery to T Cells & Hematopoietic Stem
Cells in Humanized Mice & Non-Human Primates Using
Targeting Lipid Nanoparticles
Apiwat Wangweerawong, Director, Delivery Chemistry,
Tessera Therapeutics
1.30 Discovery and HG-PRECISE Engineering of
hfCas12Max High-Fidelity Nuclease and Pre-clinical Testing
in Mouse and NHP Models to Support M.U.S.C.L.E. Trial for
DMD
TJ Cradick, Chief Technology Officer, HuidaGene
Therapeutics
2.20 In Vivo Application of Exosome-Based Genome Editing
Technology
Dave Carter, Head of Research, Evox Therapeutics
2.20 Disruption of Aberrant Splicing by Gene Editing with
a Type V CRISPR-Cas Enzyme as a Potential Treatment for
ALS
John Murphy, Chief Scientific Officer, Arbor Biotechnologies